Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

PURPOSE: Preclinical data suggest the combination of an anti–programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune check...

Descripción completa

Detalles Bibliográficos
Autores principales: Dummer, Reinhard, Long, Georgina V., Robert, Caroline, Tawbi, Hussein A., Flaherty, Keith T., Ascierto, Paolo A., Nathan, Paul D., Rutkowski, Piotr, Leonov, Oleg, Dutriaux, Caroline, Mandalà, Mario, Lorigan, Paul, Ferrucci, Pier Francesco, Grob, Jean Jacques, Meyer, Nicolas, Gogas, Helen, Stroyakovskiy, Daniil, Arance, Ana, Brase, Jan C., Green, Steven, Haas, Tomas, Masood, Aisha, Gasal, Eduard, Ribas, Antoni, Schadendorf, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061149/
https://www.ncbi.nlm.nih.gov/pubmed/35030011
http://dx.doi.org/10.1200/JCO.21.01601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061149/
https://www.ncbi.nlm.nih.gov/pubmed/35030011
http://dx.doi.org/10.1200/JCO.21.01601

Ejemplares similares